A 5-treatment, Study in Healthy Volunteers to Assess The Safety, Tolerability, and Pharmacokinetics of Four Controlled Release (CR) Pregabalin Tablet Formulations and the Immediate Release (IR) Formulation Administered Fasted

NCT01443169 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Sequence 1 - Treatment A: Controlled Release Pregabalin
DRUG: Sequence 1 - Treatment B: Controlled Release Pregabalin
DRUG: Sequence 1 - Treatment C:Controlled Release Pregabalin
DRUG: Sequence 1 - Treatment D: Controlled Release Pregabalin
DRUG: Sequence 1 - Treatment E: Immediate Release Pregabalin
DRUG: Sequence 2 - Treatment B: Controlled Release Pregabalin
DRUG: Sequence 2 - Treatment D: Controlled Release Pregabalin
DRUG: Sequence 2 - Treatment A: Controlled Release Pregabalin
DRUG: Sequence 2 - Treatment C: Controlled Release Pregabalin
DRUG: Sequence 2 - Treatment E: Immediate Release Pregabalin
DRUG: Sequence 3 - Treatment C: Controlled Release Pregabalin
DRUG: Sequence 3 - Treatment A: Controlled Release Pregabalin
DRUG: Sequence 3 - Treatment D: Controlled Release Pregabalin
DRUG: Sequence 3 - Treatment B: Controlled Release Pregabalin
DRUG: Sequence 3 - Treatment E: Immediate Release Pregabalin
DRUG: Sequence 4 - Treatment D: Controlled Release Pregabalin
DRUG: Sequence 4 - Treatment C: Controlled Release Pregabalin
DRUG: Sequence 4 - Treatment B: Controlled Release Pregabalin
DRUG: Sequence 4 - Treatment A: Controlled Release Pregabalin
DRUG: Sequence 4 - Treatment E: Immediate Release Pregabalin

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.